A Belgian court has overturned the seizure of funds from Poland's air-traffic agency PANSA, which was tied to Pfizer's €1.3 billion claim, according to Notes from Poland.
The ruling came on Thursday after PANSA challenged the freezing, arguing it was not party to the Pfizer-Poland dispute.
In July, PANSA said it had been cut off from Eurocontrol fees, which provide around 80% of its revenue.
Eurocontrol is based in Belgium, where Pfizer has pursued its legal fight against Poland over the unpaid vaccines.
The freeze was part of Pfizer's effort to collect money a Belgian court awarded it from Poland in April this year.
Prime Minister Donald Tusk promised government backing so PANSA could keep operating and said air safety would not be compromised.
PANSA said its legal challenge to the bailiffs' seizure succeeded, but noted the ruling can still be appealed.
Poland's health ministry said the Belgian court confirmed PANSA's funds belong to the agency, not the State treasury. The ministry argued PANSA is a separate legal entity not liable for State treasury obligations, so its funds cannot satisfy Pfizer's claims.
Magdalena Jaworska-Maćkowiak, who heads PANSA, told Polish Radio that the agency had been taken hostage in a matter that in fact did not involve it. She said the dispute was separate and that bridge financing could not give long-term stability under current law.
Pfizer said the ruling affected only one avenue of enforcing the April ruling and it is taking appropriate legal and contractual steps.
The row dates back to 2022, when Poland declined to take delivery of and pay for Pfizer COVID-19 vaccine doses ordered through European Union procurement agreements. Adam Niedzielski, health minister at the time, cited a force majeure clause in April 2022, after Russia launched its full-scale invasion of Ukraine.
Poland argued refugee costs strained finances and infections had fallen; Romania made a similar decision, and Pfizer sued both in Belgium in 2023. In April a Belgian court rejected Poland's arguments, ordering it to accept about 64 million doses and pay over 5.6 billion zloty plus interest and costs.



